J&J to buy eye disease biotech Ollin Biosciences for up to $3.3 billion
Johnson & Johnson said it would acquire Ollin for $2.2 billion upfront, with the potential for milestone payments of up to about $1.13 billion.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
